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Abstract 
Background 
Malignant pleural effusion is associated with short life expectancy and significant morbidity.  A recent 
randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis found that 
indwelling pleural catheters reduced time in hospital and need for additional procedures but were 
associated with excess adverse events. 
Methods 
Using data from the clinical trial, we compared costs associated with use of indwelling pleural 
catheters and with talc pleurodesis.  Resource use and adverse events were captured through case 
report forms over the 1-year trial follow up.  Costs for outpatient and inpatient visits, diagnostic 
imaging, nursing and doctor time were obtained from the NHS reference costs and University of 
Kent’s Unit Costs of Health and Social Care 2011 and inflated to 2013 using the UK Consumer 
Price Index. Procedure supply costs were obtained from the manufacturer.  Difference in mean 
costs was compared using non-parametric bootstrapping.  All costs were converted to US dollars 
using the OECD Purchasing Power Parity Index. 
Results 
Overall mean cost (SD) for managing patients with indwelling pleural catheters and talc pleurodesis was 
$4993 (5529) and $4581 (4359) respectively.  The incremental mean cost difference was $401 with a 
95% CI (-1387 to 2261). The mean cost related to ongoing drainage in the indwelling pleural catheter 
group was $1011 (732) versus $57 (213) in the talc pleurodesis group (p=0.001).  This included the cost 
of drainage bottles, dressing changes in the first month and catheter removal.  There was no significant 
difference in cost of the initial intervention or adverse events between the groups. For patients with 
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survival less than 14 weeks, IPC is significantly less costly than talc pleurodesis with mean cost 
difference of -$1719(95% CI -3376 to -85).   
Conclusion 
There is no significant difference in mean cost of managing patients with indwelling pleural 
catheters compared with talc pleurodesis.  For patients with limited survival, IPC appears less 
costly. 
Trial Registration: isrctn.org Identifier: ISRCTN87514420 
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INTRODUCTION 
Malignant pleural effusion accounts for 22% of all pleural effusions with over 150,000 cases 
diagnosed annually in the United States and more than 1 million worldwide.[1, 2] British 
Thoracic Society guidelines recommend that graded talc slurry be used as the sclerosing agent of 
choice delivered via an intercostal tube as first line management for patients with malignant 
pleural effusion (herein referred to as talc pleurodesis); indwelling pleural catheter (IPC), or 
tunneled pleural catheter, insertion is recommended for a select subgroup.  The delivery of the 
two interventions differs - talc pleurodesis requires upfront hospitalization, whereas IPC 
insertion, in general, is performed in an outpatient setting with ongoing drainage in the 
community thereafter.   
 
The effectiveness of IPC insertion and talc pleurodesis has been compared in a recent 
randomized trial. The TIME2 trial measured symptom control, the subjective relief of malignant 
pleural effusion related dyspnea, with both treatment modalities.[3]  Secondary outcomes of the 
TIME2 trial included quality of life and health care costs. Although IPCs were not found to be 
superior to talc pleurodesis for relieving dyspnea or improving quality of life, the use of IPCs 
was associated with reduced hospital stay and decreased pleural procedures, though with more 
frequent adverse events.  The only other randomized controlled trial comparing safety and 
efficacy of IPC insertion and pleurodesis for malignant pleural effusion used doxycycline as the 
sclerosant.[4] In this study of 144 patients, there was no difference in effusion recurrence rate at 
30 days, improvement in dyspnea or quality of life; however, there was a significantly shorter 
length of hospital stay in the IPC group. 
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Given the unknown impact of IPCs on resource use and costs, relative to standard care (i.e. talc 
pleurodesis), a more thorough analysis of costs is warranted prior to recommendation of the 
adoption of IPC use as first line management for patients with malignant pleural effusion.   
 
METHODS 
Objective and Overview 
Using clinical and resource data captured in the TIME2 trial, our primary objective was to 
compare total costs associated with the use of IPCs and with talc pleurodesis in patients with 
malignant pleural effusion.  In a secondary analysis, we sought to compare the costs between 
groups across different categories (the initial procedure, adverse events and those related to 
ongoing drainage).  
 
TIME2 was a randomized controlled trial, conducted in 7 centers across the UK, of 106 patients 
with confirmed malignant pleural effusion who were randomized to either IPC insertion or talc 
pleurodesis.  Ethical and regulatory approval for the study was obtained from the Milton Keynes 
research ethics committee before recruitment commenced (REC number: 07/Q1603/2). After 
written informed consent, patients were randomized to receive either talc (chest tube and talc 
slurry pleurodesis) or IPC (Rocket Medical).  IPCs were inserted in the outpatient setting (unless 
the patient was already admitted to hospital at the time of randomization in which case the 
catheter was inserted in hospital).  Patients and their caregivers were instructed on how to 
perform drainage from the catheter.  On average, the frequency of IPC drainage in the first 6 
weeks of the trial was twice weekly although this varied and was recorded in case report forms 
throughout the trial.  All patients randomized to talc pleurodesis had a chest tube inserted and 
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talc pleurodesis performed, if appropriate, in hospital.  Primary objective of the trial was to 
compare the efficacy of IPCs and talc pleurodesis at relieving dyspnea using the 100 mm visual 
analog scale.  Baseline characteristics of the patients are summarized in Table 1. 
 
We conducted a cost analysis alongside the clinical trial.  The perspective adopted for the 
valuation and costing of the intervention was that of the health care payer, therefore non-medical 
costs (i.e. patient time and travel costs, as well as costs related to lost productivity) were not 
included.  All patients were followed for 1 year or until death, whichever occurred first, and the 
costing analysis was performed over the same time frame.  The median life survival in this 
patient population was 200 days (14% were alive at 1 year) therefore no additional modeling of 
costs beyond the trial period was performed. Given that costs included in the analysis were 
incurred over the trial follow-up period (<= 1 year), discounting was not performed. 
Resources and Costs 
The resources required to manage malignant pleural effusion was based on information 
documented on trial patients’ case report forms.  Resource use throughout the trial was recorded 
throughout the study period and divided into the following categories: (1) initial intervention 
procedures and hospital length of stay (if required), (2) resources related to ongoing drainage and 
(3) adverse events, and are summarized in Table 2. 
 
Initial Intervention 
Initial intervention costs consisted of baseline chest tube insertion costs plus hospital or day case 
unit charges, depending on whether patients were treated as an inpatient or outpatient.  Baseline 
insertion costs included chest tube insertion supplies, ultrasound provision, nursing time (1hr), 
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physician time (1hr) and drainage (i.e. if additional collection bottles were used for patients with 
high volume fluid production).  In the case of patients with an IPC, we included an additional 
cost for IPC education by a nurse (duration 2 hours).  For patients undergoing talc pleurodesis, in 
addition to baseline insertion costs, we included costs related to the pleurodesis itself (i.e. 
analgesia and the need for an additional pre-pleurodesis chest radiograph).  
On-going Drainage 
The total volume of pleural fluid drainage was recorded in both study groups. Patients with IPCs 
were given a logbook after insertion of their catheter in which they were asked to record how 
often they drained their IPC and the number of bottles required. The total number of bottles used 
during the follow up period was then multiplied by the manufacturer’s acquisition cost for the 
drainage bottle.  
Adverse Events 
Data for all adverse events were collected.  A blinded reviewer (Dr. Robert Miller MBBS FRCP) 
determined if adverse events were related to the intervention.  Resource use and any additional 
procedure required as a result of an adverse event were recorded and assigned a specific 
procedural cost.  Diagnostic imaging associated with the adverse event was also noted.  Finally 
hospitalizations (including the length of stay) and the number of outpatient visits associated with 
each adverse event were recorded. 
Valuation of Resource Use 
All patients admitted to hospital were assigned a cost of hospital care using the Health Resource 
Group (HRG) ‘Pleural Effusion with major co-morbidities and complications’, taken from the 
UK National Health Service (NHS) HRG reference manual.[6]  This HRG cost was converted to 
a daily hospital cost using information on average length of stay for this Health Resource Group 
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(average length of stay = 7.7 days). We then calculated a total hospitalization cost for patients 
based on their individual length of stay.  An excess bed day cost, lower than the daily hospital 
cost noted above, was then incorporated to acknowledge the fact that the cost of hospital 
admissions tends to decrease as the number of days increases beyond a ‘trim point’ (13 days).[6] 
 
For outpatient visits, a HRG specific day-case unit cost was obtained from the NHS reference 
cost manual. Nursing and physician charges were taken from the University of Kent’s Unit Costs 
of Health and Social Care 2011.[7]  Price weights for supplies associated with the procedures 
were obtained directly from the manufacturer. All unit price weights are summarized in Table E1 
of the online data supplement.   
 
Costs in 2011 UK pounds were inflated to 2013 values using the UK Consumer Price Index 
(CPI).[8]  Using the OECD Purchasing Power Parity Index (Dec 2012), costs in UK pounds were 
converted to 2013 US dollars.[9] 
Statistical Analysis 
All analyses were calculated on an intention to treat basis. Cost data is not normally distributed 
(typically right-skewed with heavy tail); therefore to compare mean costs across groups, our 
primary analysis used non-parametric bootstrap with 1000 replications to derive a 95% 
confidence interval for the incremental mean cost difference between the two groups.  For the 
bootstrap estimate, we used the percentile method.  We randomly sampled with replacement, 
generating 1000 random samples.  Differences in mean costs for each of the 1000 samples was 
calculated, ranked from lowest to highest and difference in mean cost for the 26th and 975th 
ordered values defined the 95% confidence interval. 
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The data collection was incomplete for one main variable: the total drainage volume.  To account 
for this, drainage volume following the initial procedure was imputed based on the mean 
drainage of complete cases for each group.[10]  Missing values for drainage volume during the 
follow up period were imputed using last drainage carried forward as there was significantly 
higher inter-patient variability in drainage compared with intra-patient variability across follow 
up periods.  The proportion of drainage data missing is described further in Table E2 of the 
online data supplement. 
 
All statistical analyses were performed using Stata 11.2.  
 
Sensitivity Analysis 
To test the robustness of our base case assumptions, we performed several sensitivity analyses.  Firstly, 
procedural costs (i.e. for chest tube insertion supplies plus nursing and physician time) may have been 
included within the NHS unit price weights given for outpatient visits or inpatient stays in the NHS 
reference manual.  Therefore, we explored the impact of the cost analysis after removing all additional 
procedural costs from the day case unit and inpatient unit price weights.   
 
Secondly, our estimates of total costs did not include follow up visit costs mandated by the trial protocol 
as these were deemed to be equal between both groups.  As part of our sensitivity analyses, we 
compared mean total costs between the groups including all clinical trial protocol-related costs. 
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Thirdly, we adjusted the price of IPC drainage bottles to see if that affected the total mean cost 
difference between groups. 
 
Fourthly, there is some suggestion in the literature that the cost-effectiveness of IPC is greater in patients 
with limited life expectancy (< 3months).[11]  We compared the mean cost difference between groups in 
patients who survived longer than 14 weeks as well as in patients who died within 14 weeks of 
randomization within the trial. 
 
Lastly, our primary analysis assumed that patients or their families in the IPC group performed all 
drainage of the pleural catheters.  As part of our sensitivity analysis we assumed that patients with an 
IPC would require 2 hours of nursing care per week and compared the mean cost difference between 
groups under this scenario. 
 
RESULTS 
Baseline Characteristics 
Baseline characteristics between the two groups were similar (Table 1).[3]   
Primary Outcome, Adverse Events and Mortality 
All primary and secondary clinical outcomes are reported separately.[3]  A limited summary of 
the primary clinical outcome, adverse events and survival time from the clinical trial are reported 
in Table 3.  There was no difference in the primary clinical outcome of mean daily dyspnea over 
the first 42 days of the trial between groups.  There was no significant difference in survival time 
between groups with a mean difference of -0.8months (95% CI, -2.4 to 0.8 months; p=0.32).  
Overall, 21 of 52 patients (40%) in the IPC group vs 7 of 54 patients (13%) in the talc group 
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experienced adverse events (OR, 4.70; 95% CI, 1.75-12.60; P=.002); however, no significant 
difference was seen between groups with serious adverse events. 
Resource use 
Average resource use by each group is summarized in Table 4.  The distribution of total costs in 
each group is shown in Figure 1.   
 
Initial Procedure 
101 drains were successfully inserted, 51 in the IPC arm and 50 in the talc pleurodesis arm (2 
patients died between randomization and enrolment therefore no procedures were performed, 2 
patients had no pleural fluid, 1 patient withdrew from the study).   All patients randomized to talc 
pleurodesis were admitted to hospital while 19 patients (37%) randomized to the IPC group were 
inpatients at the time of randomization and had their IPC placed in hospital.   
 
In the talc pleurodesis group 10 patients’ (18.5%) and in the IPC group, 23 patients’ (44%) data 
were missing.  The average initial drainage was 2825ml (SD 1991ml) in the talc pleurodesis 
group, equivalent to 2 large drainage bottles (1800ml capacity); and 1776ml, equivalent to 2.96 
bottles with 600ml capacity (SD 1.04), in the IPC group.   
 
Following insertion of the catheter, the mean length of hospital stay (LOS) in the IPC group was 
2.49 days (SD 7) with a median of 0 days (IQR 0-1) after randomization.  Mean LOS in the talc 
pleurodesis group was 4.98 days (SD 3.65) with a median LOS of 4 days (IQR 2-6) after 
randomization: a difference of - 2.5 days (95% CI: -4.68 to -0.292).  For patients in the IPC 
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group already admitted to hospital at the time of randomization (N=19), mean LOS after 
randomization was 6.63 days (SD 10.3) with a median of 2 days (IQR 1-8). 
 
Follow up drainage 
Average pleural drainage for the study period was 24.8 bottles (SD 21) in the IPC group and 1.6 
bottles (SD 7) in the talc pleurodesis group.  Due to re-accumulation of patients’ pleural 
effusions (i.e. pleurodesis failure) 46 additional procedures were performed on 12 patients in the 
talc pleurodesis group.  This compared to three additional procedures on 3 patients in the IPC 
group.  Seven out of 54 patients (13%) in the talc pleurodesis group required repeat thoracentesis 
versus one patient in the IPC group.  Ten patients in the talc pleurodesis group and 2 patients in 
the IPC group required further chest tube insertion during the trial.   
 
Adverse Events 
There were a total of 28 adverse events in the IPC group and 9 adverse events in the talc 
pleurodesis group. In the IPC group, these resulted in 33 outpatient visits (n=17) and 15 
admissions to hospital (n=11) with an average length of stay of 8.86 days (SD 12).  In the talc 
pleurodesis group there were 41 additional outpatient visits (n=12) and 15 admissions to hospital 
(n=10) with an average length of stay of 5.46 days (SD 4 days).    
Costs  
Primary Analysis 
Mean costs for each group and the mean cost difference between groups are summarized in 
Table 4. The total mean cost (SD) for managing patients with IPC and talc pleurodesis was 
$4993(5529) and $4581(4359) respectively, with a mean difference of  +$401 (95% CI -1387 to 
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2261).  There was no significant difference in mean adverse event cost between groups nor was 
there a difference in significant mean cost between groups after combining the cost of initial 
intervention and ongoing drainage costs over the trial period. 
Sensitivity Analysis 
Results of the sensitivity analyses are shown in Table 5.   
 
After removing the procedural costs from patient visits (i.e. including just the day-case visit or 
hospital cost in the cost calculation), the mean cost difference between groups was not 
significant, -$54 (95% CI -1565 to 2122).  
 
Inclusion of clinical trial protocol-induced costs altered the mean total cost in each group 
however the difference between groups was not significant. 
 
We tested whether incremental reductions  in the manufacturer’s price for IPC drainage bottles 
(by 75%, 50% or 25%) had any effect on the total mean cost noting a trend towards cost savings 
with IPC; however, the confidence intervals around the estimates remained large and included a 
mean cost difference of zero. 
 
The mean cost of treating patients who survived for more than 14 weeks was $5707(1122) and 
$4625(1085) in the IPC and talc pleurodesis groups, respectively (mean difference $1098 (95% 
CI -1418 to 4010)).  For patients who died before 14 weeks, the mean cost of treating patients 
was lower in the IPC group ($2944(656)), compared with the talc pleurodesis group 
(($4671(642)) (mean difference -$1719(95% CI -3376 to -85)). 
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If we assume that patients with IPCs require nursing care of 2 hours per week for drainage and 
dressing changes, the mean cost for the IPC group increases to $6807(6225) and to $4638(4411) 
in the talc pleurodesis group resulting in a significant difference in costs of $2130 (95% CI 205 
to 4184). 
 
DISCUSSION 
Using a comprehensive costing dataset collected alongside a randomized trial over a 1 year 
period, we noted no difference in the cost of treating patients with malignant pleural effusion 
with first line IPC insertion compared with talc pleurodesis.  The talc pleurodesis group had a 
longer initial length of hospital stay but there were significantly higher costs associated with 
ongoing drainage for patients with an IPC.  Results from our sensitivity analyses suggest that 
IPC is a less costly alternative to talc pleurodesis in patients with limited survival. Alternatively, 
if patients with IPC require significant nursing support for ongoing drainage (2 hours per week 
or more), then IPC use is more costly compared to talc pleurodesis.  
 
The TIME2 trial demonstrated that both IPC and talc pleurodesis are effective in reducing 
patient-reported dyspnea symptoms in patients with malignant pleural effusions and concluded 
that the use of either IPC or talc pleurodesis should be based on patient preferences after 
discussion of the risks and benefits of each therapy.   This cost analysis shows no difference in 
overall costs between IPC and talc pleurodesis, lending support to the clinical recommendation 
that either IPC or talc pleurodesis can be used to treat malignant pleural effusions and that the 
choice of which one should be based on patient preferences, after discussion of the risks and 
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benefits of both therapies.  In addition to patient preferences, and when considering the costs of 
these two treatment options from the healthcare payer perspective, we offer the following 
recommendations: 
1. If on average, patients will require 2 or more hours of nursing care per week for drainage 
and catheter care, then IPC becomes significantly more costly and we recommend talc 
pleurodesis be considered the preferred treatment option for patients with malignant 
pleural effusions. 
2. For patients with expected survival less than 14 weeks (based on a proxy performance 
status score of 3 or 4), and without expected nursing support at home, we recommend 
IPC be considered the preferred treatment option for patients with malignant pleural 
effusions. 
3. For patients with expected survival less than 14 weeks and with expected nursing support 
of 2 or more hours/week, there is no significant cost difference between IPC and talc 
pleurodesis and therefore the choice of intervention should be based solely on patient 
preferences after informed consent. 
 
To date, no other study that we are aware of has compared the costs associated with IPC or talc 
pleurodesis using data from a randomized clinical trial.  Other studies, which have modeled the 
cost effectiveness of IPCs using observational data, show IPCs to be incrementally more costly 
than talc pleurodesis.[11, 12]  In one study, IPC insertion was noted to be cost-effective relative 
to talc pleurodesis when the life expectancy of patients was less than 6 weeks or if the 
probability of spontaneous pleurodesis with IPC was greater than 87%.[12]   
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More recently, a cost-effectiveness decision model of tunneled pleural catheters versus bedside 
pleurodesis, repeated thoracentesis and thoracoscopic talc pleurodesis found the former to be 
superior to the other therapeutic options.  An incremental cost-effectiveness ratio (cost per 
quality adjusted life year) of $49,978 relative to repeat thoracentesis was demonstrated.[11]  The 
findings of Puri et al however, were specifically in patients with limited longevity (survival less 
than 3 months), a spontaneous pleurodesis rate from IPCs of 40% and a complication rate of 5%.  
If spontaneous pleurodesis rates fell or complication rates increased the cost-effectiveness of IPC 
reduced.  When patient survival was modeled to 12 months bedside talc pleurodesis was superior 
to all other strategies.   
These results support our findings that, in a patient population with a median survival of 
approximately 6 months, IPCs have a similar cost to bedside talc pleurodesis.  Of note, our study 
suggests that the use of IPC may be associated with cost savings, compared to talc pleurodesis 
for patients who survived <14 weeks.  To our knowledge, there have been no studies published 
to date that have identified predictors of mortality in patients with malignant pleural effusion.  
This clinical information may be very helpful in identifying patients for whom the use of IPC is 
clinically indicated and ultimately cost-effective.  
 
A major strength of our study was the comprehensive and complete collection of resource data 
for patients in the trial.  In addition, as our study population has a limited life expectancy 
(median 6 months) the length of follow up for one year was sufficient to capture all clinically 
important outcomes and relevant costs associated with the intervention.[3]    
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There are several limitations of our study.  First, the sample size was chosen to determine a 
clinically important difference in breathlessness between the groups and was not powered to 
detect differences in health care costs.  Despite this, our study provides relevant information 
about the cost of both therapies.   Second, while it may be advantageous that all costs incurred 
during the period of a clinical trial are included (regardless of whether they are related to the 
intervention (e.g. all hospitalizations versus intervention related-hospitalizations)), we evaluated 
costs specific to the intervention only.  Third, the perspective of our study was that of the 
healthcare system.  Whilst this perspective is admittedly narrower than other possible 
perspectives (for example, societal perspective, which attempts to capture time costs of patients, 
caregiver burden costs and costs associated with productivity loss), the additional costs required 
to inform a societal perspective were not collected during the clinical trial.  Fourth, the overall 
IPC adverse event rate reported in the TIME2 trial was 40% compared with 13% in the talc 
pleurodesis group, higher than what has been described previously in the literature.  We believe 
this may be related to a few factors: most data in the literature has been retrospective and 
therefore actual complications recorded may be lower; and definition of adverse events vary (the 
TIME2 trial counted IPC blockage as a complication compared to other studies which did not). 
For costing purposes in our study, additional procedures required during the trial and related 
adverse events were combined.  Despite the increased number of patients with adverse events in 
the IPC group, the costs associated with adverse events were no different between groups.  This 
likely is related to the fact that serious adverse events were not significantly different between 
the groups and additional costs associated with increased pleural procedures in the talc group 
were balanced out by the increased total number of adverse events in the IPC group.  Finally, this 
study examined the differences in costs between two management approaches with similar 
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effectiveness(i.e. a cost minimization study). A full economic evaluation incorporating quality of 
life and costs would be informative to determine the cost-effectiveness of IPCs.  This evaluation 
is underway.  
 
CONCLUSION 
The overall comparative costs of managing patients with malignant pleural effusion with IPCs or talc 
pleurodesis are similar however; the resources required for the two strategies differ.  Higher initial 
hospital bed-day costs are incurred with talc pleurodesis whereas IPC insertion results in increased 
ongoing drainage costs.  IPCs become less costly compared to talc pleurodesis for patients with expected 
survival less than 14 weeks. Identifying predictors of survival in patients with malignant pleural 
effusions may be helpful in deciding which management strategy may be best for patients.  Cost savings 
with IPC may be lost if significant nursing support is required (>2hours per week).  These findings are 
important for both clinicians and healthcare decision makers.  With the information available we suggest 
that first-line management of patients with malignant effusion can include either treatment and the 
choice of patients’ treatment should be tailored to individual circumstances and goals of care. 
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Table 1. Baseline demographic data for 106 patients with malignant pleural effusion  
 IPC Talc 
Total no. 52 54 
Age, mean (SD), y 67 (11) 67 (12) 
Male:female (%male) 23:29 (44) 23:31 (43) 
Type of malignancy: 
breast 16 11 
lung 9 16 
mesothelioma 6 5 
other 21 21 
VAS dyspnea, mean (SD), mm 62 (22) 55 (26) 
VAS chest pain, mean (SD), mm 29 (30) 22 (29) 
Size of effusion on chest radiograph, % hemithorax (SD) 51 (23) 49 (25) 
EORTC QLQ-30: global health status % (SD) 37 (23) 37 (20) 
Inpatient:outpatient at enrolment (% inpatient) 19:33 (35) 22:31 (42) 
Davies HE, Mishra EK, Kahan BC, et al. JAMA 2012;307(22):2383-2389. Permission to 
reproduce received from JAMA. 
VAS = visual analogue scale, EORTC QLQ-30 = European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire (higher % means better quality of life). Other malignancies were 
colorectal (4 IPC:3 talc), ovarian (2 IPC:5 talc), adenocarcinoma of unknown primary (4 IPC: 2 talc); 
renal (3 IPC: 2 talc); sarcoma (1 IPC, 2 talc); thymoma (1 IPC, 1 talc); oesophageal (2 IPC); peritoneal 
(1 IPC, 1 talc); prostate (1 IPC); ampullary (1 IPC); leiomyosarcoma (1 IPC); melanoma (1 talc); 
Cost Analysis of Malignant Pleural Effusions 
 22 
myeloma (1 talc); nasopharyngeal (1 talc) and unknown (1 IPC, 1 talc). 1 patient in the talc group died 
prior to enrolment so no demographic data was available. 
Table 2. Resource Use Categories 
COST 
CATEGORY 
RESOURCE USE MEASUREMENT 
Initial 
Intervention 
  
 Procedure Includes procedure supply costs, ultrasound, 
nursing time(1hr), physician time(1hr) and 
drainage volume(if additional bottles used 
for high volume drainage), plus 
IPC group – IPC education by Nurse(2hrs) 
Talc group – talc pleurodesis supplies 
 Hospitalization or Day 
Case Unit 
LOS documented in hospital chart and 
recorded in CRF – calculated as discharge 
date minus enrolment date. 
For IPC patients treated as outpatient, 
daycase unit visit was recorded 
Ongoing 
Drainage 
  
 Drainage requirements Number of drainage bottles used by IPC 
patients was recorded in CRF 
Drainage assumed to be performed by 
patient 
Adverse Events   
 Severity & 
Inpatient vs. 
Outpatient 
 
Diagnostic Imaging 
 
 
Procedures 
Nature of adverse event was recorded in the 
CRF, whether it required inpatient or 
outpatient management and LOS 
 
Imaging associated with an adverse event 
was recorded in the CRF 
 
Procedures related to adverse events were 
documented in the CRF 
IPC = indwelling pleural catheter;  CRF = case report form; LOS = length of stay 
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Table 3. Summary of primary outcome, adverse events and mortality from TIME2 
randomized clinical trial 
 
 IPC Talc 
Primary Outcome 
VAS daily dyspnea over 42 days, mean (95% CI), 
mm 
24.7 (19.3 to 30.1) 24.4 (19.4 to 29.4) 
Difference in mean daily dyspnea, mean (95% 
CI),mm 
0.16 (-6.82 to 7.15; p=0.96) 
VAS change in dyspnea from baseline, mean 
decrease (95% CI), mm 
37.0 (29.2 to 44.8) 30.2 (22.0 to 38.4) 
Adverse Events* 
Serious, total number 9 5 
   Pleural infection 5 1 
   Cellulitis 1 0 
   Symptomatic fluid loculation requiring fibrinolytic 1 1 
   Catheter site metastases 0 0 
   Catheter blockage 1 1 
   Other † 1 2 
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Nonserious, total number 19 4 
   Pleural infection 2 0 
   Cellulitis 5 1 
   Symptomatic fluid loculation requiring fibrinolytic 2 0 
   Catheter site metastases 1 0 
   Catheter blockage 9 0 
   Other 0 3 
Mortality 
Median survival, days (IQR) 153 (73 to 288) 200 (39 to 392) 
Adapted from JAMA 2012;307(22):2383-2389. Permission from JAMA received. 
Abbreviations: IPC = indwelling pleural catheter, VAS = visual analogue scale, IQR = 
interquartile range 
*Total number of adverse events is listed.  A patient may have had more than 1 adverse event. 
†The serious adverse events included in the “Other” category were chest pain requiring 
readmission (1 IPC), surgical emphysema (1 talc), persistent air leak (1 talc). The 3 nonserious 
adverse events in the talc group were all chest tube displacement prior to pleurodesis. The 
complications of symptomatic fluid loculation requiring fibrinolytics, cellulitis, and blocked 
catheter in the talc group were observed in 2 patients who had IPCs inserted following failure of 
pleurodesis. 
Table 4. Resource Use, Mean Cost & Mean Cost Difference between IPC and Talc in US$ 
CATEGORY IPC Talc 
  
Resources 
Used 
Cost 
Resources Used 
Cost 
Mean(SD) Mean(SD) 
Initial Intervention 
Intervention 
procedures 
51 $797(36) 53 $476(47) 
Mean length of stay 
in days* 
2.49(7) 
$1147(2961) 
4.98(4) 
$2461(1834) 
N=51 N=51 
Day Case Visit 32 visits $325(260) 0 visits $0  
Total Initial 
Intervention Costs  
$2276(2849) $2939(1844) 
 
Total Ongoing 
drainage Costs 
$1011(732) $57(213) 
Adverse Events 
Outpatient visits† 33 $336(694) 41 $401(1440) 
Inpatient visits† 15 $1188(4453) 30 $871(2327) 
Procedures† 3 $19(76) 46 $227(694) 
Diagnostic 
Imaging‡ 
34 
$43(106) 
66 
$52(137) 
6 2 
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Total Adverse 
Events Costs 
$1653(4693) $1555(3737) 
Total Cost $4993(5529) $4581(4359) 
  
DIFFERENCE IN COSTS 
TOTAL COSTll 
Mean difference§ $401  
95% CI (-1387 to 2261) 
ADVERSE EVENTS COSTll 
Mean difference§ $76  
95% CI (-1524 to 1786) 
COMBINED INITIAL INTERVENTION & ONGOING DRAINAGE COSTll 
Mean difference§ $316  
95% CI (-603 to 1426) 
*Mean length of stay associated with insertion of initial intervention (includes those who were 
not admitted in the IPC group) 
†Total number of visits or procedures performed in each group 
‡Total number of chest x-rays (top) and CT scans (bottom) performed in each group 
§IPC minus Talc 
llBootstrap estimate of mean cost difference and 95% confidence interval 
 
 
Table 5. Impact of changes in uncertain variables on mean cost differences 
  MEAN TOTAL COST MEAN COST DIFFERENCE 
  IPC Talc (IPC - Talc) 
REDUCTION IN PRICE OF BOTTLES  
 Original price* $4993(5529) $4581(4358) $401(95% CI -1387 to 2261) 
   25%† $4444(5491) $4463(4038) -$43(95% CI -1745 to 1802) 
   50%‡  $4255(5425) $4450(4016) -$221(95% CI -1890 to 1612) 
   75%§ $4059(5360) $4439(3996) -$404(95% CI -2038 to 1412) 
COST OF PROCEDURES REMOVED FROM PATIENT VISITS  
  $3898(5187) $3919(3612) -$54(95% CI -1565 to 1798) 
CLINICAL TRIAL PROTOCOL COSTS INCLUDED IN TOTAL COSTS 
  $5406(5554) $5106(4146) $270(95% CI -1582 to 2122) 
SURVIVAL   
   Alive >14 weeks $5707(1122) $4625(1085) $1098(95% CI -1418 to 4010) 
   Alive <= 14 weeks $2944(656) $4671(642) $-1719(95% CI -3376 to -85) 
NURSING CARE REQUIRED FOR IPC DRAINAGE 
   1/week drainage (2hrs) $6807(6225) $4638(4411) $2130(95% CI 205 to 4184) 
   1/week drainage (1hr) $5838(5840) $4600(4337) $1202(95%CI -661 to 3134) 
Bottle price  
   First 4 weeks *$40.13 †$29.97 ‡$20.11 §$10.02 
   > 4 weeks *$28.11 †$21.06 ‡$14.20 §$7.02 
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Figure legends 
Figure 1. Right Skewed Distribution of Total Cost for IPC & Talc Groups 
  
 
